Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma

Inclusion Criteria

• •Diagnosis of non-Hodgkin's lymphoma (NHL) of one of the following types:
• •* Diffuse large B-cell
• •* Composite (at least 50% of tumor showing diffuse histology)
• •* Diffuse mixed cell
• •* Immunoblastic
• •Relapsed or refractory disease sensitive to initial or subsequent conventional therapy (at least a partial response)
• •Eligible for high-dose carmustine, etoposide, cytarabine, and melphalan protocol and autologous bone marrow transplantation or peripheral blood stem cell transplantation
• •Evidence of CD20 antigen expression in tumor tissue
• •Bidimensionally measurable disease
• •Adequate peripheral blood stem cells
• •* At least 15,000,000 CD34+ cells/kg or
• •* At least 25,000 granulocyte macrophage colony-forming units/kg
• •Age: 19 to 70
• •Performance status: Karnofsky 70-100%
• •Life expectancy: at least 4 months post-transplantation
• •Bilirubin less than 2.0 mg/dL
• •Creatinine less than 2.0 mg/dL
• •Cardiac ejection fraction at least 40% for any of the following criteria:
• •* Age 60 and over
• •* Significant cardiac history (myocardial infarction or congestive heart failure)
• •* Received greater than 350 mg/m\^2 of prior doxorubicin
• •DLCO at least 50% of predicted
• •HIV negative
• •Fertile patients must use effective contraception during and for at least 6 months after study participation
• •At least 4 weeks since prior biologic therapy and recovered
• •Human antimouse antibody negative
• •At least 4 weeks since prior cytotoxic chemotherapy and recovered
• •At least 4 weeks since prior radiotherapy and recovered
• •At least 4 weeks since prior immunosuppressants and recovered